NASD · Healthcare · Biotechnology · USA
Enliven Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics to address unmet medical needs through precision medicine. The company is advancing ELVN-001, a kinase inhibitor designed to treat chronic myeloid leukemia, along with other research-stage programs targeting diseases such as Graves' disease. It combines validated biological targets with differentiated chemistry to create treatments with improved therapeutic profiles.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Enliven Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on ELVN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.